ATRC vs BSX: Which Is the Better Buy in 2026?
Last updated October 2026
Short answer
BSX is the larger of the two ($64.33B market cap): the incumbent the market prices for continued execution (13.15x forward earnings, beta 0.57). ATRC is the smaller challenger ($3.00B), actually pricier on forward earnings (135.88x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
ATRC vs BSX: the tie-breaker metrics
Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | ATRC | BSX | What it tells you |
|---|---|---|---|
| Market cap | $3.00B | $64.33B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 135.88 | 13.15 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 280.81 | 17.97 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 1.25 | 0.57 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 92% of range | 5% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 5.81 | 2.58 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: BSX is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how ATRC and BSX affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ATRC and BSX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ATRC and BSX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does AtriCure (ATRC) do?
AtriCure, based in Mason, Ohio, makes devices that cardiac and thoracic surgeons use in the operating room. Its products fall into four franchises. Appendage management, led by the AtriClip family, closes off the left atrial appendage, the small pouch in the heart where most AF-related clots form, and is now the largest line at ~$64 million a quarter. Open ablation (the Isolator Synergy clamps and EnCompass clamp) lets surgeons create scar lines that block erratic electrical signals during open-heart surgery, and Isolator Synergy was the first FDA-approved device for persistent AF. Pain management, built around the cryoSPHERE probes, freezes intercostal nerves to reduce pain after chest surgery and is the fastest-growing franchise. Minimally invasive ablation, including the Hybrid AF Therapy combining surgical and catheter work, is the one line in decline.
What does Boston Scientific Corporation (BSX) do?
Boston Scientific Corporation is a Marlborough, Massachusetts-based medical device company that develops, manufactures, and markets minimally invasive devices used in interventional cardiology, electrophysiology, structural heart, peripheral interventions, endoscopy, urology, neuromodulation, and cardiac rhythm management. It reports through two broad segments: Cardiovascular, which houses the electrophysiology business (led by the Farapulse pulsed field ablation system) and the Watchman left-atrial-appendage closure franchise, and MedSurg, which spans endoscopy, urology, and neuromodulation. The company sells into hospitals and physicians across roughly 130 countries and competes at the leading edge of catheter-based and device-based procedures that substitute for more invasive surgery.
ATRC vs BSX: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- ATRC drivers: AtriClip and the appendage franchise; LeAAPS and BoxX-NoAF: expanding the patient pool.
- BSX drivers: Farapulse and the Pulsed Field Ablation Wave; Watchman Franchise Expansion.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The most visible competitive risk is pulsed field ablation. For BSX, the most immediate concern is a run of setbacks in 2026.
ATRC or BSX: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ATRC if you believe its drivers more; BSX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ATRC and BSX guides.
ATRC vs BSX: the full fundamentals
ATRC. AtriCure is valued as a growth franchise, not on current earnings. With 2026 adjusted EPS guided to ~$0.24 to $0.32 and GAAP EPS to ~$0.05 to $0.13, a price-earnings ratio is not very informative, so investors tend to look at sales and EBITDA multiples. At ~5x trailing sales and roughly 30x the midpoint of 2026 adjusted EBITDA guidance, the stock trades well above the medical equipment average of under 3x sales. That premium reflects ~77% gross margins, a dominant surgical appendage share and trial optionality. Figures are approximate as of October 2026.
BSX. Boston Scientific's trailing P/E of roughly 18x and forward multiple near 13x are far below the sustained premium the stock carried during its high-growth phase. The compression followed a decline of about 55% over the past year, while the S&P 500 rose about 17%, driven by slowing growth, repeated outlook cuts, and the September cybersecurity disruption. Third-quarter results are due October 28, 2026, with consensus near $0.74 to $0.76 of adjusted EPS on revenue of about $5.1 billion, and the analyst mean target of about $59 sits well above the $44.06 share price, so the debate is whether the lower multiple reflects fair concern about decelerating growth or an over-correction.
Headline figures (approximate, October 2026): ATRC shows revenue (ttm) ~$570 million (FY2025 ~$534.5M; Q2 2026 ~$153.6M, up 12.8%), 2026 revenue guidance ~$602 million to $610 million (~13% to 14% growth), gross margin ~77.2% in Q2 2026, up ~270 bps YoY, adjusted ebitda ~$27.3M in Q2 2026; 2026 guide ~$85M to $89M; BSX shows revenue (ttm) ~$21 billion (+7.5% YoY in Q2 2026), revenue (fy 2025) ~$20.1 billion, net income (ttm) ~$3.7 billion (profit margin ~17.5%), adjusted eps (q2 2026) $0.86 vs $0.83 est..
The bottom line: ATRC vs BSX
ATRC and BSX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ATRC and BSX exposure against your real portfolio. It is not an investment adviser.
Wondering how ATRC or BSX fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in AtriCure with AI
Connect the broker you already use and ask Walnut's AI how ATRC fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between ATRC and BSX?
+
AtriCure, based in Mason, Ohio, makes devices that cardiac and thoracic surgeons use in the operating room. Boston Scientific Corporation is a Marlborough, Massachusetts-based medical device company that develops, manufactures, and markets minimally invasive devices used in interventional cardiology, electrophysiology, structural heart, peripheral interventions, endoscopy, urology, neuromodulation, and cardiac rhythm management. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is ATRC or BSX the better stock?
+
Neither is universally better. BSX is the larger incumbent; ATRC is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, ATRC or BSX?
+
On forward P/E (as of October 2026), ATRC trades at 135.88x and BSX at 13.15x, so BSX is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both ATRC and BSX?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of ATRC vs BSX?
+
ATRC: The most visible competitive risk is pulsed field ablation. PFA catheters from Boston Scientific, Medtronic and Johnson & Johnson have made catheter ablation faster and more effective, and AtriCure's minimally invasive ablation sales fell ~21% in Q2 2026 as Hybrid procedures declined. If PFA also pulls patients away from surgical ablation, or if catheter-based appendage devices like Watchman gain ground in surgical candidates, the core franchises could slow. Clinical risk is concentrated: LeAAPS and BoxX-NoAF are long, event-driven trials, and a neutral or negative result would undercut the expansion story the stock reflects. Legal risk includes a Delaware Court of Chancery suit by former SentreHEART securityholders, filed in February 2025, alleging breach of the merger agreement's milestone provisions and seeking up to ~$260 million; the company has not accrued for it. Valuation is a risk in itself: at ~5x sales and with 2026 GAAP EPS guided to only ~$0.05 to $0.13, small misses can move the stock sharply, as the ~13% one-day drop in February 2026 showed. Other factors include hospital capital budgets, reimbursement changes, international pricing, and insider selling near highs. BSX: The most immediate concern is a run of setbacks in 2026. Management lowered its profit outlook in July on weaker Watchman demand and US electrophysiology share losses, then in September said a cybersecurity incident had disrupted manufacturing and order shipments and that it was unlikely to meet its third-quarter and full-year sales and adjusted earnings forecasts. In October it recalled 262,686 Imager II angiographic catheters because the tip may fracture or detach during use, a reminder of the product-recall and safety-signal risk inherent to medical devices. Competition is intensifying as Medtronic and Johnson and Johnson scale their own pulsed field ablation systems, which could further erode Boston Scientific's early PFA share and pressure pricing. Brokers including Baird, Truist and Mizuho trimmed price targets in mid-October 2026. Foreign exchange swings, hospital capital-spending cycles, reimbursement or regulatory changes, about $12.6 billion of debt, and integration risk from the company's acquisition strategy each add uncertainty.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ATRC or BSX; figures are approximate and dated (as of October 2026). Verify current data before investing.